A detailed history of Victory Capital Management Inc transactions in Immunovant, Inc. stock. As of the latest transaction made, Victory Capital Management Inc holds 335,360 shares of IMVT stock, worth $9.23 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
335,360
Previous 312,370 7.36%
Holding current value
$9.23 Million
Previous $8.25 Million 11.87%
% of portfolio
0.01%
Previous 0.01%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

BUY
$27.51 - $27.51 $632,454 - $632,454
22,990 Added 7.36%
335,360 $9.23 Million
Q2 2024

Aug 05, 2024

SELL
$25.1 - $31.61 $166,438 - $209,605
-6,631 Reduced 2.08%
312,370 $8.25 Million
Q1 2024

May 03, 2024

SELL
$30.27 - $43.79 $197,753 - $286,080
-6,533 Reduced 2.01%
319,001 $10.3 Million
Q4 2023

Feb 05, 2024

SELL
$31.31 - $44.19 $1.48 Million - $2.09 Million
-47,237 Reduced 12.67%
325,534 $13.7 Million
Q3 2023

Nov 06, 2023

SELL
$18.55 - $39.96 $3.81 Million - $8.21 Million
-205,364 Reduced 35.52%
372,771 $14.3 Million
Q2 2023

Jul 27, 2023

SELL
$14.2 - $23.75 $1.24 Million - $2.08 Million
-87,650 Reduced 13.16%
578,135 $11 Million
Q1 2023

May 02, 2023

BUY
$15.27 - $19.72 $10.2 Million - $13.1 Million
665,785 New
665,785 $10.3 Million
Q1 2021

May 04, 2021

SELL
$13.08 - $49.6 $90,095 - $341,644
-6,888 Closed
0 $0
Q4 2020

Feb 01, 2021

BUY
$36.36 - $52.71 $39,014 - $56,557
1,073 Added 18.45%
6,888 $318,000
Q3 2020

Nov 09, 2020

BUY
$22.61 - $38.9 $131,477 - $226,203
5,815 New
5,815 $205,000

Others Institutions Holding IMVT

About Immunovant, Inc.


  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track Victory Capital Management Inc Portfolio

Follow Victory Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.